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INTRODUCTION
S100 calcium-binding protein B (S100B) is a small 21 kDa (dimer form) secretory protein which belongs to the S-100 protein family. It was primarily derived from astrocytes and has various intra and extracellular biological roles. However, subsequent research has suggested that adipose tissue is a major source of serum S100B.
1 Concentration of S100B in adipose tissue is comparable with its content in nervous tissue.
2 Among different cell types of adipose tissue, mature adipocytes possess the highest levels of S100B. 3 Moreover, elevated S100B expression has been reported in plasma and adipocyte-enriched fraction of adipose tissue of obese animals. 4 Nutritional, metabolic and anthropometric status have recently been suggested as important factors affecting serum levels of the S100B. [5] [6] [7] [8] [9] It has been shown that serum levels of S100B decrease during chronic fasting and normalize with weight gain. 7 Steiner et al reported that S100B serum levels are strongly associated with body mass index (BMI) and reflect excess adipose tissue mass. 10 Adipocyte derived S100B is strongly related to the arrangement of cellular energy metabolism and up-regulation of S100B has been attributed to metabolic disturbances including changes in glucose metabolism. 6 A close association has been indicated between increased S100B levels with insulin resistance 6 and visceral obesity. 8 Increased S100B level has also been reported in hypertensive patients. 9 Most of these indicators have been defined as features of metabolic syndrome (MetS).
The metabolic syndrome is characterized by a combination of conditions including central obesity, dyslipidemia, high 14 and hypertension, 15 all related with a higher risk for the development of MetS. Besides, adipose tissue dysfunction goes along through changes in serum S100B levels. 4 Therefore, a link between MetS and serum levels of S100B has been proposed but conclusive evidence is missing. We aimed to investigate serum levels of S100B in probands with MetS without a prior history of psychiatric or neurological disorders and also to study the connection of S100B with components of MetS.
MATERIALS AND METHODS Participants
Eighty eight adult volunteers (aged 30 -50 years) were recruited from a medical weight loss center using convenience sampling method. A power calculation based on mean ± SD of S100B protein from previously published data, 16 with 5% significance level test (α = 0.05), power of 90% (β = 0. Inclusion criteria for MetS group comprised having at least 3 of 5 ATP (III) criteria as follows: abdominal obesity, given as waist circumference (WC) > 88 cm for women and > 102 for men, serum triglyceride (TG) ≥ 150 mg/dL, high-density lipoprotein cholesterol (HDL-c) < 50 mg/dL for women and < 40 mg/dL for men, blood pressure ≥ 130/85 mm Hg, fasting blood glucose (FBG) ≥ 100 mg/dL. Exclusion criteria were body mass index (BMI) ≥ 40 kg/m 2 , infectious or chronic inflammatory diseases, history of psychiatric diseases, receiving anti-obesity, anti-inflammatory or antihypertensive medications, thyroid disorders, endocrine diseases, smoking, excessive consumption of alcohol, pregnancy and lactating, menopause and diet therapy during three months prior to the study.
The subjects' anthropometry parameters including body weight, height and waist circumference (WC) were measured and BMI was calculated. Finally, systolic and diastolic blood pressure (SBP and DBP, respectively) was measured.
Biochemical assessments
After an overnight fasting, five ml of venous blood was collected and serum were separated and stored at -70°C until analysis.
The levels of serum total cholesterol (TC), HDL-c and TG were measured by enzymatic colorimetric methods.
Serum LDL-c was calculated by Friedewald equation. Fasting blood sugar were determined by the glucose oxidase method. Insulin levels were determined by insulin ELISA method and the homeostasis model assessment (HOMA-IR)-insulin sensitivity was calculated. S100B levels were measured by the ELISA method according to the protocol provided by the manufactures (Eastbiopharm CO., LTD).
Statistical analyses
Normally distributed data were summarized by mean ± standard deviation (SD) and the differences between the two groups were assessed by independent sample t-test. Nonparametric variables were presented as median (percentile 25, 75) and their differences between two groups were assessed by Mann-Whitney U test. Spearman's coefficient test was used to assess the correlation between S100B with measured variables. Data analysis was performed by SPSS 16 Software and p values less than 0.05 were considered as statistically significant.
RESULTS

Demographic characteristics
There was no significant difference in age between the groups ( Table 1) . As expected, mean body weight, WC and BMI were significantly higher in MetS group as compared with control group (all p < 0.0001). The participants with MetS had higher systolic (non-significant, p = 0.06) and diastolic (p = 0.01) blood pressure than the controls. Serum concentrations of TC, TG, LDL-c, FBG, insulin, HOMA-IR were significantly higher and HDL-c lower in the MetS group than the control group (Table 1) .
Serum levels of S100B and its association with components of MetS
As shown in Fig. 1 , the participants with MetS had significantly higher levels of S100B [59.91 (35.30, 97.36) pg/mL] than those in the control group [17.12 (0.00, 47.07) pg/mL] (p < 0.0001). Serum levels of S100B protein positively correlated with WC (rho = 0.26; p = 0.01) and serum levels of TG (rho = 0.26; p = 0.01), but was not significantly correlated with HDL-c, FBG, SBP and DBP ( Table 2 ). As shown in Table 3 , subjects with abdominal obesity had higher serum levels of S100B (p = 0.02), with serum TG levels ≥ 150 than those with <150 (p = 0.03) and also among those with hypertension as compared with normotensive individuals (p = 0.01).
Association of S100B protein with demographic, anthropometric and metabolic parameters
As shown in Table 4 , serum levels of S100B protein did not significantly correlate with age, gender, BMI, serum levels of insulin, insulin resistance, TC and LDL-c levels.
DISCUSSION
In the present study, patients with MetS had higher levels of S100B than those in the control group and circulating S100B levels were positively correlated with abdominal obesity. Few researchers have studied S100B levels in metabolic diseases. Enhanced circulating levels of S100B have been mostly reported in neuropsychiatric disorders including schizophrenia, 6 Parkinson's disease 17 depression, 18 Alzheimer's disease 19 and it is ascribed to glial pathologies. According to evidences, adipose tissue mass seems to be alternatively accountable. In animal models, increased white adipose tissue S100B gene expression and also enhanced plasma levels of S100B related to obesity have been reported by Buckman et al. 4 Elevated serum levels of S100B have also been observed in obese individuals with obstructive sleep apnea-hypopnea syndrome. 20, 21 O'Connell et al in a study on schizophrenia patients have indicated that female subjects, not male patients, had higher serum levels of S100B compared to controls which was positively correlated with BMI. 22 Steiner et al have demonstrated that up regulated S100B serum levels in schizophrenia is associated with abdominal obesity and insulin resistance. 8 Taken all together, it appears that adipose tissue mass might be determinant of serum S100B levels. Astrocytes dysfunction is another possibility to explain increased S100B serum levels in patients with MetS. It has been shown that astrocytic process plasticity is crucial for the central modulation of metabolic status via management of extracellular neurotransmitter levels. 23 Astrocytic plasticity is impaired by chronic overnutrition or metabolic inflammation. Inflamed astrocytes lead to metabolic imbalance and thus MetS. 23 However, further research is needed to differentiate the effect of adipose tissue mass and astrocytes on serum S100B level.
In this study, a direct relationship was also noticed between S100B and serum levels of TG. We also observed that serum S100B levels were higher in individuals with TG levels equal or greater than 150 mg/dL. There is apparently lack of evidence regarding the connection between S100B and TG. Nevertheless, according to previous investigations, it is proposed that S100B increases TG level through involvement in lipolysis. 24 Higher circulating levels of lipolysis controlling hormones (including glucagon, adrenaline, isoproterenol, norepinephrine, ACTH, and dibutyryl cyclic AMP) have been indicated in patients with 
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BMI: body mass index; WC: waist circumference; SBP: systolic blood pressure; DBP: diastolic blood pressure; TC: total cholesterol; TG: triglyceride; LDL-C: low density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol; FBG: fasting blood glucose; HOMA-IR: homeostatic model assessment-insulin resistance. All data were expressed as mean ± SD, except insulin and HOMA-IR which were expressed as median (percentile 25, 75). * p values were reported based on independent samples t -test. † p values were reported based on Mann-Whitney U test. [25] [26] [27] It has been suggested that these hormones induce increased release of S100B protein by adipocytes which consequently leads to elevated lipolysis. 5, 28, 29 The enhanced free fatty acids during lipolysis leads to increased TG level. 30 However, further studies are needed to obtain definitive evidences« to link S100B to TG.
In the present study, the subjects with hypertension had higher levels of S100B. The finding was in agreement with earlier investigations. Higher serum S100B levels have been reported in hypertensive patients compared to controls. 31 Cannon et al. have also indicated that subjects with higher concentrations of S100B had significantly higher carotid SBP than those with low levels of S100B. 9 Further, Sherstnev et al. have indicated that serum levels of S100B can be used as possible predictors of arterial hypertension. 32 Possibly, increased S100B level in hypertensive patients is an adaptive response to catecholamines enhancement in these subjects. 33, 34 It has been reported that catecholamine injection induces S100B mRNA and protein in myocardial tissue, ventricular myocytes and increased S100B in arterial tissues. 35, 36 However, the role of S100B in pressor responses to catecholamine stimulation is unclear.
In the current study, serum S100B level was not related to serum levels of FBG and HDL-c. Investigation in these topics is really scarce. In agreement with our findings, there was only one study by Refay et al addressing the relationship between S100B and these biomarkers. They have reported that serum S100B level was negatively correlated with serum HDL level but not with FBG in MetS patients. 37 The negative correlation between S100B and HDL-c was also observed in the present study but it was statistically nonsignificant. This poor correlation could be attributed to MetS severity in the patients. In Refay et al study nearly half of the subjects met the full criteria for MetS.
Increased S100B level in MetS patients may elicit two important metabolic responses including promotion of inflammation and enhancement of blood pressure. In the adipose tissue, secretion of pro-inflammatory cytokines such as TNF-α from macrophages is known to be regulated by adipocyte derived S100B. 3 Further, extracellular S100B, in higher concentrations, acts as an immunomodulatory compound where it stimulates expression of various proinflammatory cytokines. 3 Besides, as mentioned earlier, increased release of S100B protein by adipocytes induces lipolysis which further leads to increased TG level and subsequently to atherosclerosis and hypertension. 23, 24 Thus, it is speculated that increased S100B levels could be considered as a key factor contributing in the pathogenesis of cardiovascular disorders in patients with MetS.
The most important limitation of the study was its crosssectional design. Thus, the directions of cause and effect could not be determined. Therefore, the association among variables must be interpreted with caution. The relatively small sample size was another limitation of the study and further larger studies are required to confirm these results. 
